X4 Pharmaceuticals (XFOR) Announces Strategic Restructuring

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to X4 Pharmaceuticals (XFOR) Announces Strategic Restructuring

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

February 6, 2025 7:35 AM EST

Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropenia
on track for mid-2025

Right-sizing commercial efforts to optimize XOLREMDI promotion and
support U.S. WHIM syndrome community

Restructuring impact expected to extend cash runway into first half of 2026

BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, announced today a restructuring of its workforce and capital... More